Takeda Ireland Ltd.
What Top Employers say about themselves
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Takeda Ireland Ltd - Bray (DP)
Established in 1997 Takeda Ireland – Bray, is a Solid Oral Dosage Facility, which produces, packs and ships key strategic granulates, solid oral dosage tablets and final packaged blockbuster drug products to the worldwide markets including the major US, European, Japanese and valuable emerging markets. Bray produces products for the therapeutic areas of Cardiovascular, Metabolic, Central Nervous System (CNS) and Gastro-Intestinal.
Bray, currently has over 300 employees and is a shift operation, presently working twenty-four hours a day, seven days a week. To enable this, Takeda Ireland – Bray draws on the expertise of its world-class people, equipment and systems to meet the challenges of competing in our leading-edge markets. Starting in 2019 Bray is adding to its product portfolio and expanding facilities in order to produce two new oncology drugs, with commercial production scheduled for 2021.
Takeda Ireland Ltd - Grange Castle (API, DP and Biologics)
Constructed in 2002, the site now consists of 3 plants and employs over 200 people, with plans to continue expanding into 2021. The site represents a key strategic addition to the group's global production network.
Grange Castle started out developing and producing API's from clinical trial stages through to launch and full commercialisation. In 2017/2018 the site expanded it’s API operation to include a dedicated plant for the production of API, Drug Product and Packaging to support the production of a high tech oncology product for the treatment of multiple myeloma. In 2019, the Company also established a new standalone modular cell therapy facility dedicated to manufacturing a novel stem cell therapy, locally administered for the potential treatment of certain patients with perianal fistulae associated with Crohn’s disease.
Number of employees:
Number of active countries: 70
Our comprehensive independent research revealed that Takeda Ireland Ltd. provides exceptional employee conditions, nurtures and develops talent throughout all levels of the organisation and has demonstrated its leadership status in the HR environment, always striving to optimise its employment practices and to develop its employees.
We help your organisation adapt to the rapidly changing HR environmentHow we certify